Recursion Pharmaceuticals (RXRX) Return on Invested Capital (2024 - 2026)

Recursion Pharmaceuticals' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.16% for Q1 2026.

• Quarterly Return on Invested Capital rose 3.0% year-over-year to 0.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.16% (up 3.0% YoY) and the FY2025 annual result came in at 0.74%, up 39.0% from the prior year.
• Return on Invested Capital was 0.16% for Q1 2026 at Recursion Pharmaceuticals, up from 0.19% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.16% in Q1 2026 and bottomed at 90.6% in Q1 2024.
• A 3-year average of 10.34% and a median of 0.21% in 2025 frame the typical range for Return on Invested Capital.
• Annual changes were most pronounced in 2025 — Return on Invested Capital jumped 9040 bps — and 2026, when it advanced 3 bps.
• Recursion Pharmaceuticals' Return on Invested Capital stood at 0.23% in 2024, then increased by 20 bps to 0.19% in 2025, then gained by 12 bps to 0.16% in 2026.
• Business Quant data shows RXRX's Return on Invested Capital at 0.16% in Q1 2026, 0.19% in Q4 2025, and 0.21% in Q3 2025.